Indiana Biosciences Research Institute
 Innovation Building 1 at 16 Tech Innovation District | |
| Formation | May 1, 2013 |
|---|---|
| Type | Research Institute |
| Headquarters | Indianapolis, Indiana, U.S. |
Region served | Indiana |
| Staff | 100 |
| Website | http://indianabiosciences.org |
The Indiana Biosciences Research Institute (IBRI) is an American nonprofit translational research organization headquartered in Indianapolis, Indiana, United States[1] within the 16 Tech Innovation District.[2] The IBRI is the nation's first industry-led collaborative life sciences research institute.[3] Its primary focus is on better understanding the pathogenesis of type 1 and type 2 diabetes to translate this knowledge into novel therapies,[4] while also expanding into other metabolic diseases that share common systems and pathways.[5]
History
[edit]In 2012, pharmaceutical executive John C. Lechleiter from Eli Lilly & Company initially proposed the IBRI.[6][7] In 2013, Indiana governor Mike Pence announced the formation of the IBRI.[8] Pence later worked with life sciences leaders to secure $25 million in startup funds from the state.[9]
In 2015, the IBRI hired David Broecker as CEO.[10] In late 2015, the Indianapolis City-County Council approved $75 million to build a technology park called 16 Tech.[11]
In February 2016, IBRI, along with Governor Mike Pence, announced $100 million in new funding from the Lily Endownment Inc. and the Eli Lilly and Company Foundation.[12] Later that year, in October, the IBRI hired Rainer Fischer as Chief Scientific Officer.[13][14]
In 2017, Governor Eric Holcomb reaffirmed the commitment made by his predecessor Mike Pence.[15][16][17] In August of that same year, Innovation Officer Rainer Fischer was named CEO.[18] He stepped down in 2019.[19] In September 2020, Alan Palkowitz was named president and CEO of the IBRI.[20]
In September 2024, IBRI and Indiana University announced the creation of a joint center of excellence. The new center, the Joint Center of Excellence for Point of Care, will advance innovation and treatment in four disease areas: diabetes and metabolism, pediatric rare diseases, cancer, and Alzheimer's disease.[21]
Leadership
[edit] |
Appointees to the IBRI’s Board of Directors include:
- Robert Bernhard, University of Notre Dame
- Wayne Burris, Roche Diagnostics
- Kenneth Custer, Eli Lilly & Company
- Daniel Evans Jr., Indiana University Health
- Tatiana Foroud, Indiana University School of Medicine
- Jay Hess, Indiana University
- David Ingram, Indiana University Health
- Cris Johnston, Indiana Office of Management and Budget
- John Lechleiter, Eli Lilly & Company
- Patricia Martin, BioCrossroads, Inc.
- Theresa Mayer, Purdue University
- Hany Moselhi, Roche Diagnostics
- Alan Palkowitz, IBRI
- Dan Peterson, Cook Group
- Aaron Schacht, BiomEdit, LLC
- Wendy Srnic, Corteva
- Bill Stephan, Indiana University
References
[edit]- ^ Rudavsky, Shari (February 24, 2016). "New biosciences institute gets $100M". Indianapolis Star. Retrieved June 22, 2017.
- ^ Orr, Susan (March 16, 2022). "16 Tech Promotes Emily Krueger to Chief Executive". Indianapolis Business Journal. Retrieved August 15, 2022.
- ^ "Bioscience Research Institute Creates a 'Petri Dish' for Innovation". Crain Communications. June 30, 2016. Retrieved June 22, 2017.
- ^ "IBRI Welcomes New Leader". Inside INdiana Business. Retrieved 2022-08-16.
- ^ "How We Study Alzheimer's and Potential Treatments". Indiana University Precision Health Initiative, Healthcare Triage. Retrieved 2022-08-16.
- ^ Lechleiter, John (March 31, 2015). "From hunting to farming, medicines development takes a big leap forward". Forbes. Retrieved June 22, 2017.
- ^ Pogorelc, Deanna (May 30, 2013). "Eli Lilly, Roche, device makers collaborate on new public-private research institute in Indiana". MedCity News. Retrieved June 22, 2017.
- ^ Pence, Mike (May 30, 2013). "Governor Pence Announces Indiana Biosciences Research Institute". YouTube. Retrieved June 22, 2017.
- ^ Nather, David (July 16, 2016). "With Pence pick, Trump just made women's health a top-tier election issue". PBS. Retrieved June 22, 2017.
- ^ Swiatek, Jeff (May 19, 2015). "New CEO of bioscience institute looks to hire researchers, raise millions". Indianapolis Star. Retrieved June 22, 2017.
- ^ Eason, Brian (November 9, 2015). "City-County Council OKs $75M for Indianapolis tech park". USA Today. Retrieved June 22, 2017.
- ^ "Governor Pence Joins Indiana Biosciences Research Institute to Announce $100 Million in Grants Supporting Scientific Innovation". The Indiana Republican Party. 2016-02-24. Retrieved 2024-10-01.
- ^ Ober, Andy (October 4, 2016). "IBRI hires European bioscience giant". Inside INdiana Business. Retrieved June 22, 2017.
- ^ Russell, John (April 1, 2017). "FOCUS: Biosciences institute's chief scientific officer aims to foster commercialization". Indianapolis Business Journal. Retrieved June 22, 2017.
- ^ Redman, Mary-Rachel (January 16, 2017). "Roche CEO: IBRI Will Succeed Where Others Have Failed". Inside INdiana Business. Retrieved June 22, 2017.
- ^ Lange, Kaitlin (April 21, 2017). "How Gov. Holcomb's priorities fared in the state budget". Indianapolis Star. Retrieved June 22, 2017.
- ^ Heinz, Katie (January 5, 2017). "Governor-elect Eric Holcomb unveils 2017 legislative agenda". WRTV. Retrieved June 22, 2017.
- ^ "Indiana Biosciences Research Institute Names Dr. Rainer Fischer CEO". BioSpace. 2017-09-01. Retrieved 2024-10-24.
- ^ "Indiana Biosciences Research Institute's top exec steps down, citing health problems". Indianapolis Business Journal. 2019-04-17. Retrieved 2024-10-24.
- ^ "Palkowitz named Indiana Biosciences Research Institute President and CEO". news. 2020-09-02. Retrieved 2024-10-24.
- ^ "IU, Indiana Biosciences Research Institute form center to advance point-of-care precision medicine". news.iu.edu. Retrieved 2024-11-11.